Cabozantinib improves survival in advanced hepatocellular cancer

Cabozantinib improves survival in advanced hepatocellular cancer

(HealthDay)—Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to a study published in the July 5 issue of the New England Journal of Medicine.

Ghassan K. Abou-Alfa, M.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues randomized 707 patients with advanced hepatocellular carcinoma in a 2-to-1 ratio to receive cabozantinib or matching placebo. Participants had received previous treatment with sorafenib and had disease progression after one or more systemic treatments for hepatocellular carcinoma.

The trial showed significantly longer overall survival with cabozantinib than placebo at the second planned interim analysis. The researchers found that the median overall survival was 10.2 and 8.0 months with cabozantinib and placebo, respectively (hazard ratio for death, 0.76). Median progression-free survival was 5.2 and 1.9 months with cabozantinib and placebo, respectively (hazard ratio for or death, 0.44); the objective response rates were 4 and <1 percent, respectively. Grade 3 or 4 adverse events occurred in 68 and 36 percent of patients in the cabozantinib and placebo groups, respectively. The most common high-grade events were palmar-plantar erythrodysesthesia, hypertension, increased aspartate aminotransferase level, fatigue, and diarrhea, which were all more common with cabozantinib.

"Among patients with previously treated advanced hepatocellular , treatment with cabozantinib resulted in longer overall survival and progression-free survival than ," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Exelixis, which manufactures cabozantinib and funded the study.

Explore further

Nivolumab plus ipilimumab tops sunitinib for advanced renal CA

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2018 HealthDay. All rights reserved.

Citation: Cabozantinib improves survival in advanced hepatocellular cancer (2018, July 8) retrieved 17 September 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more